The Department of Pancreatic, Hepatobiliary Surgery, Cancer Hospital of Fudan University has been treating pancreatic cancer with a variety of breakthrough treatments, which have significantly improved the quality of life of patients, and they have a cool name in the industry – the professional “bomb disposal unit” of pancreatic cancer. Invited experts: Dr. Xu Wenyan, chief physician, professor, doctoral supervisor, director of Fudan University Pancreatic Cancer Institute, and director of Pancreatic Hepatobiliary Surgery Department of Fudan University Cancer Hospital. Visiting hours: Tuesday morning, Thursday morning. Specialties: comprehensive diagnosis and treatment of pancreatic tumors, neuroendocrine tumors, mesenchymal tumors, benign and malignant tumors of liver, gallbladder and spleen, benign and malignant tumors of duodenum. He has been practicing medicine for 20 years and has performed more than 1000 pancreatic tumor surgeries and 1500 hepatobiliary tumor surgeries. The Department of Pancreatic, Hepatobiliary Surgery of Cancer Hospital of Fudan University has treated pancreatic cancer through various breakthrough treatments, which has significantly improved the quality of life of patients, and they have a cool name in the industry – the professional “bomb disposal unit” for pancreatic tumors. Optimized anastomosis technique prevents pancreatic fistula The pancreas is wrapped between the duodenum, jejunum, spleen, liver, and covered by the stomach and transverse colon in front. The surgical resection had to remove a portion of the stomach and jejunum along with the tumor, all of the duodenum, the gallbladder, and part of the common bile duct. After resection, complete reconstruction of the connections of many organs of the GI tract, including the pancreatic intestine and bile intestine, is required. The most critical reconstruction is the pancreatic duct-jejunum mucosal anastomosis, which can result in pancreatic fistula if not done carefully. This is the most common and fatal complication of pancreatic surgery. The traditional pancreatic duct-jejunum mucosal anastomosis technique is currently the most commonly used anastomosis technique internationally, but the incidence of pancreatic fistula remains high. Under the leadership of my teacher, Professor Ni Quanxing, we improved and optimized the traditional anastomosis technique, and creatively developed the “stump closed internal support pancreatic-jejunal anastomosis” and “artificial papilla embedded pancreatic-jejunal anastomosis”. -The incidence of postoperative pancreatic fistula has been reduced to less than 10%, and there is no serious tertiary pancreatic fistula, which also significantly reduces the patient’s hospitalization time and medical costs. This further increases the size of the anastomosis and simplifies the difficulty of the anastomosis. This approach was the first of its kind for us, making a Chinese voice heard in a field of surgery that has long been monopolized by Europe and the United States.” Intraoperative precision radiotherapy improves prognosis Patients with progressive or advanced inoperable pancreatic cancer generally require multiple anti-tumor combination treatments, including radiotherapy, interventional, and Chinese medicine treatments. Professor Yu Xian F, director of the Department of Pancreatic, Hepatobiliary Surgery, Cancer Hospital of Fudan University, introduced that we currently conduct weekly multidisciplinary discussions on pancreatic, hepatobiliary tumors as well as a specialized multidisciplinary clinic for rare pancreatic tumors, with Professor Ni Quanxing, director of the Pancreatic Cancer Specialty Committee of the Chinese Anti-Cancer Association, as the chief expert. Radiotherapy plays a very important role in improving the prognosis of progressive pancreatic cancer, but the special anatomical location of the pancreas makes the effect of external radiation radiotherapy for pancreatic cancer very limited. Intraoperative radiotherapy is to treat the tumor lesion with a larger dose of radiation under the condition of direct intraoperative vision, which has the advantages of precision, high surface dose and less damage to normal tissues. In addition, the application of laparoscopic technology to intraoperative radiotherapy for locally advanced pancreatic cancer has solved the problems caused by traditional intraoperative radiotherapy, such as large trauma and slow recovery. It also saves the operation time and patients can recover from the operation in 3 days so that they can receive other comprehensive treatments, which brings new hope for patients with intermediate and advanced pancreatic cancer, who previously accounted for nearly 80% of the total number of cases, and can improve the prognosis of patients. Many patients with locally advanced pancreatic cancer are inoperable due to the tumor encircling the aorta, so how to convert these patients into operable patients and turn the inoperable into possible is a question that Prof. Yu Xian-F has been thinking about in recent years. ” It is a pity that locally advanced patients do not have distant metastasis and are not operated, but direct surgery may not be resectable or the surgery is very risky due to the encapsulation of large arteries. If there are more sensitive treatment options that allow the tumor to regress briefly, it would allow this group of patients to regain access to surgery.” Professor Yu considered Abraxane, a new type of albumin-binding paclitaxel, which utilizes innovative nanoparticle albumin-binding technology to deliver paclitaxel directly to the tumor mesenchyme. Professor Yu Xianjuan combined the results of foreign studies on Abraxane with the previous observation of the efficacy of Abraxane in the domestic population, and was the first to carry out a clinical trial on Abraxane-related pancreatic cancer conversion therapy and neoadjuvant therapy in the international arena, which showed that a large proportion of patients with locally progressive stage were converted to operable patients after treatment with Abraxane and other drugs, increasing the rate of surgical resection. The results showed that a large proportion of patients with locally progressive pancreatic cancer became operable after treatment with Abraxane and other drugs, increasing the rate of surgical resection and significantly improving the prognosis. Department introduction: The Department of Pancreatic, Hepatobiliary Surgery of the Cancer Hospital of Fudan University is the largest pancreatic cancer specialty in China. Under the leadership of Professor Ni Quanxing, the honorary director of the department, and Professor Yu Xian F, the current director of the department, the team receives more than 30,000 outpatient consultations for pancreatic tumors each year, and treats more than 2,000 cases of pancreatic tumors each year, including 700 cases of radical resection of pancreatic tumors and more than 1,000 cases of comprehensive treatment including minimally invasive laparoscopic resection of pancreatic tumors, endoscopy, intervention, chemotherapy and radiotherapy, which is a leading position in China.